Improving Survival in Mantle Cell Lymphoma

Maintenance rituximab following R-CHOP induction therapy improved overall survival in nontransplant-eligible patients aged 60 or older.

Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous B-cell non-Hodgkin lymphoma that is highly responsive to induction chemoimmunotherapy. However, response duration is short for most patients.

To compare the effectiveness of two induction regimens and assess the role of maintenance immunotherapy in MCL, European investigators conducted a multinational phase III trial involving 560 nontransplant-eligible patients (age, ≥60) with previously untreated disease. Patients were randomized to eight cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) every 21 days versus six cycles of R-FC (rituximab, fludarabine, and cyclophosphamide) every 28 days. Responding patients were then randomized …

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee